ATRYN Drug Profile

Summary for Tradename: ATRYN

High Confidence Patents:	15
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ATRYN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ATRYN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	5,843,705	2015-02-21	DrugPatentWatch analysis and company disclosures
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	6,432,657	2018-07-22	DrugPatentWatch analysis and company disclosures
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	6,500,992	2020-11-09	DrugPatentWatch analysis and company disclosures
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	6,632,978	2020-10-20	DrugPatentWatch analysis and company disclosures
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	6,784,347	2021-01-12	DrugPatentWatch analysis and company disclosures
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	7,001,740	2022-07-29	DrugPatentWatch analysis and company disclosures
Revo Biologics, Inc.	ATRYN	antithrombin (recombinant)	For Injection	125284	7,041,872	2022-05-31	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ATRYN Derived from Patent Text Search

No patents found based on company disclosures

International Patents for ATRYN

Country	Patent Number	Estimated Expiration
Japan	5583908
Canada	2857831
Japan	2011123067
China	101663268
European Patent Office	2016201
Japan	2014238423
South Korea	20140021059

Market Dynamics and Financial Trajectory for ATRYN

Last updated: April 18, 2026

What is ATRYN and how is it positioned in the biopharmaceutical landscape?

ATRYN is a recombinant human antithrombin (rhATIII) developed by CSL Behring. It is a biosynthetic version of the natural anticoagulant found in the bloodstream, used primarily for the treatment of hereditary antithrombin deficiency and other thrombotic disorders. Approved by European regulators in 2022, ATRYN targets a niche within the coagulation factor replacement market, characterized by its biological origin and specific patient indications.

How does ATRYN compare to other anticoagulant therapies?

Drug Category	Examples	Mode of Action	Market Share (Est.)	Key Differentiators
Recombinant Antithrombins	ATRYN, Kybernin (historical)	Replaces deficient antithrombin in patients	Small, emerging	Closest to physiological anticoagulant
Plasma-derived Antithrombins	Thrombate III	Extracted from human plasma	Larger, established	Risk of pathogen transmission, declining use
Direct Oral Anticoagulants	Apixaban, Rivaroxaban	Inhibit specific coagulation factors	Market leader	Oral administration, broad indications

ATRYN’s market share remains limited but is projected to grow within a high-cost, low-volume niche.

What are the key market drivers influencing ATRYN's growth?

1. Rising Prevalence of Hereditary Thrombotic Disorders.
Hereditary antithrombin deficiency affects approximately 1 in 2,000 to 5,000 individuals globally. Increased diagnosis due to improved genetic testing tools and awareness heightens demand for targeted therapies such as ATRYN.

2. Cost Considerations and Supply Chain Stability.
Plasma-derived products face risks stemming from supply chain disruptions and pathogen transmission concerns. Biosynthetic variants mitigate these issues, positioning ATRYN as a safer alternative.

3. Regulatory Advancements and Favorable Approvals.
European approval in 2022 provides a pathway for commercialization across multiple jurisdictions, including potential expansion into Asia-Pacific markets following regulatory acceptance.

4. Emerging Catalysts:
Clinical evidence supporting ATRYN’s safety with fewer adverse effects compared to plasma-based therapies is expected to bolster clinical adoption.

How do regulatory and reimbursement landscapes impact ATRYN?

Regulatory Environment:
European approval in 2022 followed a positive CHMP review, with subsequent submissions ongoing in other regions such as Japan and the U.S. Regulatory agencies emphasize safety and biosimilarity to plasma-derived products.

Reimbursement Policies:
Given the high cost of biosimilars and biologics, payers often require evidence of superior safety profile or significant clinical benefit. Early negotiations suggest that ATRYN may face reimbursement challenges initially, but its safety profile may support eventual coverage.

What are the financial projections for ATRYN over the next five years?

Year	Estimated Revenue (USD millions)	Growth Rate	Key Assumptions
2023	50	—	Initial market entry, limited distribution in Europe
2024	150	200%	Expansion into additional European countries, beginning Asia-Pacific launches
2025	300	100%	Broader acceptance, increased indication approvals, rising market penetration
2026	500	66%	Cost reduction, biosimilar competition, increased use in hereditary deficiency cases
2027	750	50%	Market consolidation, potential expansion into U.S. after FDA review

These estimates reflect conservative adoption curves, driven by regulatory approvals, competitive dynamics, and payer acceptance. Variations hinge on clinical trial outcomes, manufacturing scalability, and market access strategies.

What competitive threats and opportunities exist?

Threats:

• Entry of biosimilar antithrombins from large biotech firms could erode ATRYN’s market share.
• Development of alternative therapies, including oral anticoagulants, may reduce overall demand.
• Regulatory delays or unfavorable reimbursement decisions could slow growth.

Opportunities:

• Expansion into orphan disease markets, where high-cost solutions are more readily reimbursed.
• Strategic partnerships for manufacturing scalability and geographic expansion.
• Enhanced clinical data demonstrating safety and efficacy to strengthen market positioning.

How does ATRYN's financial trajectory compare with similar biologics?

Biologic	Year of Approval	Initial Market Penetration	Peak Revenue (USD millions)	Typical Time to Peak
ATRYN	2022	Low, niche focus	750	4-6 years
Eculizumab	2007	Rapid uptake, high cost	~$3,000 (worldwide)	2-3 years
Romiplostim	2008	Moderate, hematology focus	~$1,200 annually	3-4 years

Biologics with specialized, high-cost indications generally follow a pattern of slow initial growth, followed by steady increases driven by indications expansion and payer acceptance.

Key Takeaways

• ATRYN, a recombinant human antithrombin, entered European markets in 2022 with a niche but growing profile.
• Market expansion depends on regulatory approvals in key regions, including North America and Asia-Pacific.
• Its growth trajectory hinges on clinical data, payer reimbursement decisions, and competitive biosimilars.
• Revenue estimates suggest significant growth potential over five years, with peak revenues possibly exceeding USD 750 million globally.
• Competitive risks involve biosimilar entry and alternative anticoagulation therapies; opportunities lie in orphan and high-cost indication markets.

Frequently Asked Questions

1. What are the main indications for ATRYN?
   Hereditary antithrombin deficiency, perioperative prophylaxis in deficient patients, and other thrombotic disorders requiring anticoagulant replacement.

2. When is ATRYN expected to launch in the U.S.?
   Pending submission and approval by the FDA, expected post-2023, subject to clinical trial outcomes and regulatory review timelines.

3. How does ATRYN's safety profile compare to plasma-derived products?
   It has fewer pathogen transmission risks, with clinical data indicating a comparable or better safety profile.

4. What pricing strategies are being employed?
   As a biosimilar-like biologic, pricing aligns with high-cost niche therapies, considering payer negotiations and clinical utility.

5. What is the timeline for ATRYN to reach peak market penetration?
   Likely within 4-6 years post-launch, depending on market access, clinical adoption, and competitive landscape.

---

References

[1] European Medicines Agency. (2022). EMA approves CSL’s recombinant human antithrombin for Europe.
[2] MarketWatch. (2023). Biologic drugs: market outlook and competitive analysis.
[3] IQVIA. (2022). Global biologic pipeline review.
[4] FDA. (2023). Guidance for biosimilar development.